Does Ox Bile Help Fatty Liver? Evidence & Risks

Does ox bile help fatty liver? It is a question increasingly asked by people looking for ways to support liver health beyond conventional advice. Ox bile supplements, derived from dried cattle bile, are widely available without prescription and are often marketed as digestive aids. While there is a plausible theoretical basis for their use, rooted in the role bile acids play in fat metabolism and liver signalling, the clinical evidence in humans remains very limited. This article explains what ox bile is, how it is thought to work, its potential risks, and what NHS guidance actually recommends for managing fatty liver disease.

What is fatty liver and why does bile matter?

Fatty liver disease involves excess fat accumulating in liver cells, and bile acids play a key role in fat emulsification and metabolic signalling via receptors such as FXR and TGR5, though altered bile acid profiles in MASLD do not yet have proven clinical significance.

Fatty liver disease occurs when excess fat accumulates within liver cells, and bile plays a role in how the liver processes dietary fats. The condition is broadly divided into two categories: metabolic dysfunction-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and alcohol-related liver disease (ALD). Both involve disrupted fat metabolism, and both can progress to more serious conditions such as liver fibrosis or cirrhosis if left unmanaged. The NHS and the British Liver Trust provide patient-facing information on MASLD and its risk factors.

Bile is a digestive fluid produced by the liver and stored in the gallbladder. It is composed of bile acids, cholesterol, phospholipids, and water. Its primary function is to emulsify dietary fats in the small intestine, breaking them into smaller droplets that digestive enzymes can act upon more efficiently. Without adequate bile, fat absorption becomes impaired and fat-soluble vitamins (A, D, E and K) may not be absorbed properly.

Bile acids also act as signalling molecules. They interact with receptors such as the farnesoid X receptor (FXR) and TGR5, which are involved in regulating glucose metabolism, insulin sensitivity, and inflammation.^[15][16] Alterations in bile acid profiles have been observed in people with MASLD, though the direction of causality and clinical significance of these changes are not fully established.^[14][15] The hypothesis that restoring bile acid signalling might benefit liver health is hypothesis-generating rather than proven in humans, and should be interpreted with caution.

What is ox bile and how is it thought to work?

Ox bile supplements theoretically improve fat digestion and FXR signalling, but no large, well-designed randomised controlled trials have shown they reduce liver fat or prevent disease progression in humans.

Ox bile is a supplement derived from the dried bile of cattle. There is currently no robust clinical evidence from large, well-designed randomised controlled trials to confirm that ox bile supplements effectively treat or reverse fatty liver disease in humans. Ox bile supplements are widely available without prescription and are often marketed to support digestion, particularly fat digestion. They typically contain a mixture of bile acids, including cholic acid and deoxycholic acid, which are naturally present in bovine bile.

The proposed mechanism is that supplementing with exogenous bile acids could theoretically compensate for impaired bile flow or altered bile acid composition, thereby improving fat emulsification. Some proponents also suggest that ox bile may activate FXR signalling pathways, which could theoretically reduce hepatic fat accumulation and inflammation. These remain theoretical mechanisms based largely on animal models or small laboratory studies; translation to human clinical benefit has not been demonstrated.

It is worth distinguishing ox bile supplements from pharmaceutical bile acid therapies. Ursodeoxycholic acid (UDCA) is a licensed medicine in the UK, indicated for conditions including primary biliary cholangitis; its licensed indications and prescribing information are set out in the relevant UK Summary of Product Characteristics (SmPC) on the electronic Medicines Compendium (emc).^[7][8] UDCA is not the same as ox bile, and its evidence base is considerably stronger. Obeticholic acid (Ocaliva), an FXR agonist, is licensed in the UK for primary biliary cholangitis but does not hold a licence for MASLD; its UK SmPC confirms this.^[9][10] Neither of these medicines is equivalent to an ox bile supplement.

In summary, while the theoretical rationale for ox bile supplementation in fatty liver is plausible at a mechanistic level, it remains speculative. No large, well-designed randomised controlled trials have demonstrated that ox bile supplements reduce liver fat, improve liver enzymes, or prevent disease progression in people with MASLD or ALD.

Are there any risks or side effects of taking ox bile supplements?

Common side effects include diarrhoea, nausea, bloating, and cramping; people with gallstones, bile duct obstruction, or inflammatory bowel disease face additional risks and should seek medical advice before use.

Ox bile supplements carry a number of potential risks and side effects, and people with liver or gallbladder conditions should exercise particular caution before taking them. Because ox bile supplements are classified as food supplements rather than medicines in the UK, they are not regulated by the MHRA in the same way as licensed medicines.^[11] The Food Standards Agency (FSA) oversees food supplement safety in the UK, but supplements are not subject to the same rigorous pre-market safety, quality, or efficacy testing required for pharmaceutical products.^[12]

Commonly reported side effects of ox bile supplementation include:

• Diarrhoea or loose stools, particularly at higher doses

• Nausea or stomach discomfort

• Bloating and flatulence

• Abdominal cramping

These effects are consistent with the known actions of bile acids on gut motility and fluid secretion. More significant concerns arise in specific populations. People who have had their gallbladder removed (cholecystectomy) already experience altered bile acid dynamics, and additional supplementation may worsen diarrhoea or bile acid malabsorption.^[17] Those with active gallstones, bile duct obstruction, or inflammatory bowel disease should avoid ox bile supplements unless under direct medical supervision, as increased bile acid load could exacerbate these conditions. These cautions reflect theoretical risk based on the pharmacology of bile acids; specific safety data for ox bile supplements in these groups are limited.

Regarding potential interactions with medicines: if you take any prescription medicines, including those for cholesterol or other long-term conditions, speak to your GP or pharmacist before starting any supplement. Do not stop or adjust prescribed medicines on the basis of supplement use. Pregnant or breastfeeding individuals should avoid ox bile supplements due to the absence of safety data in these groups.

If you experience persistent abdominal pain, jaundice, dark urine, or pale stools after taking any supplement, contact your GP promptly. These symptoms may indicate a liver or bile duct problem requiring investigation. Suspected adverse reactions to supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What does NHS guidance say about treating fatty liver?

NHS and NICE guideline NG49 do not recommend ox bile supplements; evidence-based management of MASLD centres on sustained weight reduction, a balanced diet, regular physical activity, and management of associated conditions such as type 2 diabetes.

NHS and NICE guidance does not recommend ox bile supplements as a treatment for fatty liver disease. The evidence-based management of MASLD centres on lifestyle modification. NICE guideline NG49 (Non-alcoholic fatty liver disease: assessment and management, published 2016 and subsequently updated) sets out the UK framework for assessment and management; MASLD is the current internationally agreed terminology for what NG49 calls NAFLD, and the two terms refer to the same condition.^[1]

NICE NG49 and NHS guidance recommend that initial assessment in primary care includes blood tests and, where appropriate, non-invasive fibrosis scoring. The FIB-4 score is used as a first-line tool to assess the likelihood of advanced fibrosis; where the result is indeterminate or elevated, further assessment with the Enhanced Liver Fibrosis (ELF) test or referral to hepatology may be considered.^[2][13] People with suspected advanced fibrosis are referred to a hepatologist. Specific thresholds and local referral pathways are set by individual Integrated Care Boards (ICBs) and should be confirmed with your GP.

Key NHS-recommended approaches to managing MASLD include:

• Achieving a sustained reduction in body weight of around 7 to 10 per cent, which evidence cited in NICE NG49 associates with meaningful reductions in liver fat and inflammation^[1][18]

• Following a balanced, reduced-calorie diet low in saturated fat, refined carbohydrates, and added sugars

• Engaging in at least 150 minutes of moderate-intensity aerobic activity per week, in line with NHS physical activity guidelines

• Avoiding alcohol entirely or reducing intake significantly, particularly in alcohol-related liver disease

• Managing associated conditions such as type 2 diabetes, hypertension, and dyslipidaemia, which contribute to liver disease progression

For people with type 2 diabetes or obesity and MASLD, certain licensed medicines may be considered by a clinician. GLP-1 receptor agonists have been studied in clinical trials and have shown reductions in liver fat and markers of liver inflammation in people with obesity or type 2 diabetes (for example, the LEAN trial with liraglutide and the NEJM 2021 semaglutide NASH trial).^[6] These medicines are not currently licensed specifically for MASLD, and their use in this context would be guided by a clinician based on the individual's overall clinical picture. They are prescription-only medicines and are not available over the counter.

If you are concerned about fatty liver disease, the appropriate first step is to speak with your GP, who can arrange blood tests and imaging to assess liver health and refer you to a hepatologist if needed. Self-treating with unregulated supplements is not a substitute for medical evaluation. Bolt Pharmacy is a GPhC-registered online pharmacy in Great Britain offering online consultations with prescriber review and pharmacist support, where clinically appropriate treatment options may be discussed.

Scientific References

1. Metabolic dysfunction-associated steatotic liver disease (MASLD): assessment and management (NG49).
2. Assessment for advanced liver fibrosis in people with MASLD (NG49 chapter).
3. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (Newsome et al.).
4. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (PubMed record).
5. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (Sanyal et al.).
6. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial.
7. Ursodeoxycholic acid 250mg Hard Capsules – UK Summary of Product Characteristics.
8. Ursodeoxycholic acid – BNF NICE.
9. Ocaliva (obeticholic acid) – EPAR Product Information.
10. Obeticholic acid – BNF NICE.
11. Nutrition legislation information sheet – food supplements and medicinal status.
12. Food Standards Agency – official website.
13. Sequential Diagnostic Approach Using FIB-4 and ELF for Advanced Fibrosis in MASLD (Kang et al.).
14. Plasma and fecal bile acids profiles in metabolic dysfunction-associated steatotic liver disease with advanced fibrosis. Am J Physiol Endocrinol Metab..
15. Natural bioactive compounds reprogram bile acid metabolism in MAFLD: Multi-target mechanisms and therapeutic implications. Int Immunopharmacol..
16. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sin B..
17. Managing bile acid diarrhea: aspects of contention. Expert Rev Gastroenterol Hepatol..
18. AGA Clinical Practice Update on the Evaluation and Management of Metabolic Dysfunction- and Alcohol-Associated Liver Disease: Expert Review. Clin Gastroenterol Hepatol..
19. Global epidemiological patterns and disease burden of MASLD, MetALD, and ALD. Clin Mol Hepatol..

Frequently Asked Questions